6:54 PM
 | 
Dec 11, 2012
 |  BC Extra  |  Clinical News

Biotie reports Parkinson's data for tozadenant

Biotie Therapies Corp. (HSE:BTH1V) said twice-daily oral tozadenant for 12 weeks met the primary endpoint of reducing mean daily "off" time in which patients experienced symptoms of their Parkinson's disease (PD) vs. placebo in a Phase IIb...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >